Associated tags: Intelligence, Patient safety, Automation, Pharmacy, Omnicell, Approximation error, Prescription, Health, Pharmaceutical, OMCL, Software, Practice Management, Hospitals, Data Management
Locations: UNITED STATES, NORTH AMERICA, TEXAS, NEVADA, NV
Technology,
Other Retail,
Other Technology,
Software,
Networks,
General Health,
Pharmaceutical,
Health,
Data Management,
Retail,
Company,
Twitter,
Pharmacy,
Automation,
OMCL,
Prescription,
Conference,
LinkedIn,
Population,
Patient safety,
Approximation error,
Disclosure,
United Kingdom,
Solution,
Regulation Fair Disclosure,
Intelligence,
Nasdaq,
Investor relations,
Hospital Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter of 2021 before the open of the market on Tuesday, November 2, 2021.
Key Points:
- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter of 2021 before the open of the market on Tuesday, November 2, 2021.
- The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m.
- Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs.
- Omnicell and the Omnicell logo are registered trademarks of Omnicell, Inc. in the United States and other countries.
Retrieved on:
Thursday, September 9, 2021
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare.
Key Points:
- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare.
- This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the expected benefits of the acquisition of the FDS Amplicare business, including on Omnicells non-GAAP EBITDA and non-GAAP earnings per share, the impact of the acquisition on Omnicells products and services and the capabilities of the products and services of the FDS Amplicare business.
- Baird served as financial advisor to FDS Amplicare, and Willkie Farr & Gallagher served as legal counsel to FDS Amplicare.
- OMNICELL, the Omnicell logo and EnlivenHealth are registered trademarks or trademarks of Omnicell, Inc. or one of its subsidiaries.
Retrieved on:
Tuesday, September 7, 2021
Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has opened a new software development center via its India subsidiary based in Bangalore, India.
Key Points:
- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has opened a new software development center via its India subsidiary based in Bangalore, India.
- The new Omnicell India software development center will be led by Ved Singh, who joins Omnicell as Vice President, Software Engineering.
- Ved brings more than 24 years of experience in building products across cloud-based artificial intelligence platforms, enterprise software, and mobile applications.
- Ved will be instrumental in delivering software services that will support the Omnicell Cloud platform, combining his experience in cloud-based product and platform development with scaling teams from the ground up.
Retrieved on:
Wednesday, August 18, 2021
Data Management,
Health,
Technology,
Practice Management,
Other Technology,
Software,
Pharmaceutical,
Cloud,
Prescription,
Population,
Workflow,
Private Securities Litigation Reform Act,
Annual report,
EM,
Syringe,
Software,
Adoption,
U.S. Securities and Exchange Commission,
Technology,
PIS,
CSD,
OMCL,
Patient safety,
Security (finance),
Efficiency,
Pharmacy,
Nasdaq,
Risk,
Approximation error,
Automation,
Forward-looking statement,
Fresenius (company),
Health,
Intelligence,
United Kingdom,
Partnership,
Solution,
Form 10-K,
Medicine,
3D printing,
Risk management The Summer 2021 Release is designed to deliver greater process efficiency, expand automation to support medication workflows, and provide greater intelligence for workflow optimization.
Key Points:
- The Summer 2021 Release is designed to deliver greater process efficiency, expand automation to support medication workflows, and provide greater intelligence for workflow optimization.
- The release also provides greater platform deployment options, offering customers more flexibility and improving time to value for strategic initiatives.
- With the Summer 2021 Release, health system leaders now have the option to elevate their pharmacy operations with greater scalability through Cloud-Hosted OmniCenter.
- OMNICELL and OMNICENTER are registered trademarks and the Omnicell logo and Omnicell One are trademarks of Omnicell, Inc. All other trademarks are property of respective third-party partners.
Software,
Practice Management,
Pharmaceutical,
Internet,
Health,
Data management,
Hospitals,
Technology,
Spartanburg Regional Healthcare System,
Spartanburg, South Carolina,
Omnicell,
Automation,
Pharmacies,
Pharmacy automation,
SRHS,
States of the United States,
Cities in the United States,
Articles,
Spartanburg Regional Healthcare System,
Omnicell,
SPARTANBURG REGIONAL HEALTHCARE SYSTEM,
OMNICELL It introduces groundbreaking pharmacy automation technologythe Omnicell XR2 systemalong with dedicated resources to support operation and best practice optimization to help eliminate errors during medication dispensing and enhance inventory control, leading to improved clinical and financial outcomes.
Key Points:
- It introduces groundbreaking pharmacy automation technologythe Omnicell XR2 systemalong with dedicated resources to support operation and best practice optimization to help eliminate errors during medication dispensing and enhance inventory control, leading to improved clinical and financial outcomes.
- Through Omnicell One, a cloud-based intelligence service, Spartanburg Regional expects to gain the visibility, insights, and workflow tools needed to drive improvements in medication inventory optimization, medication waste reduction, and drug diversion monitoring.
- Spartanburg Regional Healthcare System (SRHS) offers a full spectrum of services through six hospital campuses: Spartanburg Medical Center, Spartanburg Medical CenterMary Black Campus, Pelham Medical Center, Cherokee Medical Center, Spartanburg Hospital for Restorative Care and Union Medical Center.
- Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs.
Software,
Practice Management,
Pharmaceutical,
Managed care,
Health,
Data management,
Hospitals,
Technology,
Law firms,
Omnicell,
Willkie Farr & Gallagher,
Sidley,
Evercore,
Willkie,
FDS Amplicare,
Omnicell,
FDS AMPLICARE,
OMNICELL "The COVID-19 pandemic has accelerated the transformation to the New Era Pharmacy, said Adam McMullin, chief executive officer, FDS Amplicare.
Key Points:
- "The COVID-19 pandemic has accelerated the transformation to the New Era Pharmacy, said Adam McMullin, chief executive officer, FDS Amplicare.
- Evercore served as financial advisor and provided a fairness opinion to Omnicell and Sidley Austin LLP served as legal counsel to Omnicell.
- Baird served as financial advisor to FDS Amplicare, and Willkie Farr & Gallagher served as legal counsel to FDS Amplicare.
- OMNICELL, the Omnicell logo and EnlivenHealth are registered trademarks or trademarks of Omnicell, Inc. or one of its subsidiaries.
Data management,
Health,
Technology,
Practice Management,
Managed care,
Software,
Pharmaceutical,
Articles,
Randall Lipps,
Business,
Omnicell,
Intellectual property law,
Lipps,
Trademark,
Board of directors,
Marketing We are pleased to welcome Ed to the Omnicell Board of Directors, said Randall Lipps, Chairman, President, Chief Executive Officer, and Founder of Omnicell.
Key Points:
- We are pleased to welcome Ed to the Omnicell Board of Directors, said Randall Lipps, Chairman, President, Chief Executive Officer, and Founder of Omnicell.
- The addition of Mr. Bousa to Omnicells Board is part of the Boards ongoing refreshment process, which has resulted in the addition of two highly qualified new directors since 2019.
- I am delighted to be joining the Omnicell Board at such an exciting time for the Company, said Mr. Bousa.
- Omnicell is a registered trademark and the Omnicell logo is a trademark of Omnicell, Inc. in the United States and other countries.
Data management,
Health,
Technology,
Hospitals,
Software,
Pharmaceutical,
Health sciences,
Health,
Omnicell,
Pharmacy,
Adherence Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter of 2021 before the open of the market on Thursday, July 29, 2021.
Key Points:
- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter of 2021 before the open of the market on Thursday, July 29, 2021.
- The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m.
- Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs.
- Omnicell and the Omnicell logo are registered trademarks of Omnicell, Inc. in the United States and other countries.
Software,
Supply chain management,
Pharmaceutical,
Oncology,
Specialty,
Technology,
Hospitals,
Fitness & Nutrition,
Retail,
Biotechnology,
Practice Management,
Health,
Health,
Pharmacy,
Doctor of Pharmacy,
Pharmacist,
Chemotherapy,
Compounding,
Barcode,
Omnicell,
Chartwell Pennsylvania, LP,
CarepathRx,
Omnicell,
CHARTWELL PENNSYLVANIA, LP,
CAREPATHRX,
OMNICELL Chartwell Pennsylvania, LP , the nations leading health-system based provider of home infusion, specialty pharmacy, and enteral nutrition, has partnered with Omnicell to install their IVX Workflow sterile compounding technology to manage chemotherapy drug product preparations.
Key Points:
- Chartwell Pennsylvania, LP , the nations leading health-system based provider of home infusion, specialty pharmacy, and enteral nutrition, has partnered with Omnicell to install their IVX Workflow sterile compounding technology to manage chemotherapy drug product preparations.
- Developing new and innovative competencies with this type of technology further enhances CarepathRxs leadership role in the health-system direct home infusion treatment space.
- The use of Omnicells IVX Workflow allows Chartwell technicians to implement a step-by-step preparation of chemotherapy that employs gravimetric verification and barcode-scanning.
- In addition to barcode scanning and gravimetrics, Chartwell implemented automated photography to give our pharmacists the ability to review each step throughout the IV preparation, said Kyra Wivagg, PharmD, Manager of Pharmacy Operations at Chartwell.
